Found: 12
Select item for more details and to access through your institution.
Exploratory pharmacodynamics and efficacy of PF-06817024 in a Phase 1 study of patients with chronic rhinosinusitis and atopic dermatitis.
- Published in:
- Allergy, Asthma & Clinical Immunology, 2024, v. 20, n. 1, p. 1, doi. 10.1186/s13223-024-00894-8
- By:
- Publication type:
- Article
Microarray analysis uncovers retinoid targets in human bronchial epithelial cells.
- Published in:
- Oncogene, 2003, v. 22, n. 31, p. 4924, doi. 10.1038/sj.onc.1206728
- By:
- Publication type:
- Article
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial.
- Published in:
- Arthritis & Rheumatology, 2023, v. 75, n. 8, p. 1370, doi. 10.1002/art.42519
- By:
- Publication type:
- Article
Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
- Published in:
- Arthritis & Rheumatology, 2020, v. 72, n. 10, p. 1621, doi. 10.1002/art.41316
- By:
- Publication type:
- Article
A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a <sup>14</sup>C‐Microtracer Approach.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 7, p. 815, doi. 10.1002/cpdd.1109
- By:
- Publication type:
- Article
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis
- Published in:
- Arthritis Research & Therapy, 2024, v. 26, n. 1, p. 1, doi. 10.1186/s13075-024-03337-2
- By:
- Publication type:
- Article
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study.
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 1, p. 33, doi. 10.1093/bjd/ljad098
- By:
- Publication type:
- Article
Efficacy and safety of topical brepocitinib for the treatment of mild‐to‐moderate atopic dermatitis: a phase IIb, randomized, double‐blind, vehicle‐controlled, dose‐ranging and parallel‐group study*.
- Published in:
- British Journal of Dermatology, 2022, v. 187, n. 6, p. 878, doi. 10.1111/bjd.21826
- By:
- Publication type:
- Article
Discovering in vivo cytokine-eQTL interactions from a lupus clinical trial.
- Published in:
- Genome Biology, 2018, v. 19, n. 1, p. N.PAG, doi. 10.1186/s13059-018-1560-8
- By:
- Publication type:
- Article
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF‐06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study
- Published in:
- Journal of Clinical Pharmacology, 2024, v. 64, n. 5, p. 529, doi. 10.1002/jcph.2360
- By:
- Publication type:
- Article
Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: A phase I, first-in-human study.
- Published in:
- Journal of Clinical Pharmacology, 2014, v. 54, n. 1, p. 14, doi. 10.1002/jcph.158
- By:
- Publication type:
- Article
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article